Company News
Feature article
October 2, 205
Ready for the next phase of growth
A spotlight on BioPorto’s mission to transform kidney care, and insights from new CEO, Carsten Buhl, on BioPorto’s strategic direction. Read More
announcements
June 10, 2025
New CEO Appointed as Part of Company Succession Planning
Carsten Buhl will join as BioPorto Group CEO, effective September 1, 2025. Current CEO Peter Mørch Eriksen will remain in place until then and following to support a smooth and effective transition. Read More
announcements
March 20, 2025
BioPorto Announces 2024 Annual Results; Releases Annual Report
2024 was marked by significant accomplishments and strategic progress – overall revenue growth of 17% and 34% growth in the US. Annual Report | Presentation
Announcements
October 29, 2024
First Patient Enrolled
BioPorto is excited to announce that the first patient in its US study of ProNephro AKI™ (NGAL) for adult use has been enrolled at Massachusetts General Hospital. Read More
Announcements
October 10, 2024
Principal Investigator and CRO Named for US Adult Clinical Study
Dr. Andrew Allegretti, MD, MSC of Massachusetts General Hospital, has been appointed PI for the adult cutoff study and ProPharma has been selected as the CRO. Read More